James C. Swayzee
James Swayzee is an independent consultant to several life sciences companies in the US and Europe.
His current clients are biopharma start-ups in the areas of oncology, neurology, infectious disease, and vascular disease who seek his advice on strategies for corporate and clinical development as well as interactions with industry.
Until his 2007 retirement as a life sciences partner at Accenture, he led projects to build or transform client capabilities in sales and marketing, strategy, and business development. Examples of major engagements include design of a new global operating model for a mid-sized German company, transforming business development activities at two top-five pharma companies, and preparing an international presence strategy and operating model for a major Japanese pharmaceutical company.
Mr. Swayzee joined Accenture after a 12-year career at Eli Lilly & Co that included diverse responsibilities that gave him unique exposure to all aspects of the industry’s value chain. His last position at Lilly was Director of Corporate Business Development where he had responsibility for acquisitions, alliances, and licensing, creating new business opportunities through partnerships with European life science companies. Prior to this assignment, Mr. Swayzee spent nearly four years as General Manager of Lilly’s pharmaceutical operations in France, its largest subsidiary outside the US. Lilly posted Mr. Swayzee to France following two years as the company’s first Director of Corporate Strategic Planning where he worked extensively with heads of R&D, manufacturing, and commercial operations to coordinate long- and medium-range planning. Before this, he held positions in sales, sales management, new product planning, and product launch preparation in Lilly’s US organization.